Drug Profile

Enibarcimab - Adrenomed

Alternative Names: Adrecizumab - Adrenomed; HAM 8101

Latest Information Update: 28 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adrenomed
Class Anti-infectives; Antivirals; Heart failure therapies; Monoclonal antibodies
Mechanism of Action Adrenomedullin modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Acute heart failure; COVID 2019 infections; Septic shock

Most Recent Events

20 May 2026 AdrenoMed announces intention to submit marketing applications to US FDA and EMA
20 May 2026 US FDA and EMA recommends positive feedback of enibarcimab supporting late stage development plan including phase III registrational trial
20 May 2026 AdrenoMed plans a registrational phase III trial for in USA and European Union

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com